title: In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.
abstract: Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC90(0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.
authors.affiliation: Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA kwaites@uabmc.edu.
authors.forename: Ken B
authors.initials: KB
authors.lastname: Waites
authors.affiliation: Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
authors.forename: Donna M
authors.initials: DM
authors.lastname: Crabb
authors.affiliation: Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
authors.forename: Lynn B
authors.initials: LB
authors.lastname: Duffy
authors.affiliation: Sexually Transmitted Bacterial Infections, Research and Development, Statens Serum Institut, Copenhagen, Denmark.
authors.forename: Jorgen S
authors.identifier: 0000-0002-7464-7435
authors.initials: JS
authors.lastname: Jensen
authors.affiliation: Institute of Antibiotics, Huashan Hospital, Fudan University, and China Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Nabriva Therapeutics AG, Vienna, Austria.
authors.forename: Susanne
authors.initials: S
authors.lastname: Paukner
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D002681:China; D004224:Diterpenes / Q000494:pharmacology; D004318:Doxycycline / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000494:pharmacology; D005060:Europe; D024841:Fluoroquinolones / Q000494:pharmacology; D018942:Macrolides / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009177:Mycoplasma pneumoniae / Q000187:drug effects*; D011083:Polycyclic Compounds; D014481:United States; D000097567:Pleuromutilins
chemical_list: D000900:Anti-Bacterial Agents; D017963:Azithromycin; D004224:Diterpenes; D004318:Doxycycline; D004917:Erythromycin; D024841:Fluoroquinolones; D018942:Macrolides; D000077266:Moxifloxacin; D011083:Polycyclic Compounds; D000097567:Pleuromutilins
keywords: Mycoplasma pneumoniae; lefamulin; pleuromutilin; pneumonia; susceptibility testing